Meta-analysis · people

Retatrutide: systolic blood pressure down 6.79 mmHg in meta-analysis

Checked against the paper Meta-analysisPublished by PepVault

The takeaway

Pooled trial data link retatrutide to lower blood pressure, total and LDL cholesterol and triglycerides, with no significant change in HDL.

Kind
Meta-analysis
Studied in
People
Published
2026
Journal
High Blood Press Cardiovasc Prev

What they tested

The team set out to test whether retatrutide changes blood pressure and blood fat levels, based on all the randomized trials they could find.

How the study was done

A systematic review and meta-analysis that pooled randomized controlled trials of retatrutide found in PubMed, Cochrane Library, Scopus and ClinicalTrials.gov. Results were combined with a random-effects model, a method that allows for real differences between trials.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking retatrutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Across the trials, retatrutide lowered systolic blood pressure (the top number) by a weighted mean difference of 6.79 mmHg and diastolic blood pressure (the bottom number) by 2.46 mmHg. A weighted mean difference is an averaged gap between treated and comparison groups. Total cholesterol fell by 21.88 mg/dL, LDL-C (the so-called bad cholesterol) by 13.10 mg/dL and triglycerides (a blood fat) by 40.90 mg/dL, all with p < 0.0001. HDL-C (the so-called good cholesterol) showed no significant change, at -0.01 mg/dL (p = 0.98).

What it doesn’t show

The total cholesterol result varied a lot from trial to trial (I2 = 84%), so that number is less steady than the blood pressure results. The analysis looked at blood pressure and blood fat markers, not at heart attacks, strokes or other heart events.

The paper

Simental-Mendía et al. Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials. High Blood Press Cardiovasc Prev. 2026.

The compound

More studies on Retatrutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking retatrutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo